| Open: | 0.53 | High: | 0.5384 | | Low: | 0.51 | Volume: | 324,536 | | Yield: | n/a | P/E Ratio: | n/a | | Bid: | n/a | Ask: | n/a | | Ex Div. Date: | n/a | Ex Div. Amount: | n/a |
| Overview: |
GenVec, Inc. (GenVec) is a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer. TNFerade is also being evaluated for use in the treatment of other types of cancer. Using its core adenovector technology, TNFerade stimulates the production of tumor necrosis factor alpha (TNF alpha), a known anti-tumor protein, in cells of the tumor. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop vaccines using its adenovector technology. The Company is developing a vaccine in animal health against foot-and-mouth disease (FMD) and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus (RSV) and Herpes Simplex Virus Type 2 (HSV-2).
More from Reuters »
|
| Contact: |
No information available. |
Spam Report:  |
No GNVC Stock Spam reported. |
|
Subscribe to our newsletter to get free stock market tips and investment advice! (348 subscribers)
RSS Feed
XHTML
RSS